THU0183 Cigarette smoking and antiphospholipid antibodies in systemic lupus erythematosus

Background Patients with systemic lupus erythematosus (SLE) have an increased risk for cardiovascular disease (CVD). In previous prospective studies both smoking and antiphospholipid antibodies (aPL) had a significant impact on CVD risk in SLE. Smoking can in other settings induce autoantibodies. Objectives To investigate the potential association between smoking and aPL in SLE patients. Methods 367 prevalent SLE patients from a single center were included. Clinical evaluation and data on smoking habits were recorded at inclusion. aPL (anticardiolipin antibodies (aCL) IgG/IgM, anti-b 2 glycoprotein-1 (ab 2 GP1)) and the lupus anticoagulant (LAC) were measured using standard methods. Logistic regressions evaluated the association between smoking (ever, former, current) at inclusion and antibody status. Never smokers were used as reference. Results In multivariable models adjusted for age, sex and age at disease onset, ever smoking was associated with LAC, aCL IgG and ab 2 GP1 IgG, and this association was primarily driven by former smokers (p Conclusions Smoking is known to accelerate atherosclerosis, additionally we demonstrate that a history of smoking is associated with pro-thrombotic aPL among SLE patients. This association was particularly evident among former smokers. Further studies are needed to investigate mechanisms behind these observed associations. Disclosure of Interest None Declared